Tafamidis was designed to delay impairment to nerve function caused by the toxic aggregation of a normally harmless protein called transthyretin and is currently approved for use in both Europe and Japan. However, the FDA has called for further clinical proof before approving the drug for use in the United States.
Hey, if it's bad or neutral, keep your confidence levels real tight, 5% or 1%. For science.
If it's for good, loosen up your confidence levels for "clinical proof."